● Recruiting

Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced Malignant Pleural Mesothelioma

Condition: Malignant Pleural Mesothelioma, Advanced · Sponsor: Tianjin Medical University Second Hospital

PhaseN/A

Planned participants15

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

The purpose of this study is to evaluate the efficacy and safety of Oncolytic Adenovirus(H101) combined with PD-1 inhibitor in patients with advanced malignant pleural mesothelioma who have previously been resistant to advanced PD-1 inhibitors.

This description comes directly from the study's public registry record.

Talk to the study team

Haitao Wang, Ph.D · +86-022-88326385 · peterrock2000@126.com

Jinhuan Wang, Ph.D · +86-022-88326610 · wjhhappy2008@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Tianjin Medical Unversity Second Hospital

Tianjin, Tianjin Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06031636